



## Chugai Selected for the Second Consecutive Year for the Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment

TOKYO, September 16, 2015 -- Chugai Pharmaceutical Co., Ltd. [Head office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama] (Chugai) (TOKYO: 4519) announced that it has been selected for the second consecutive year as an index component of the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific). This index is the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which is one of the world's premier indices for Socially Responsible Investment (SRI).

The DJSI is a leading SRI index, jointly compiled by S&P Dow Jones Indices LLC of the United States and RobecoSAM AG of Switzerland, which serves as one of the most important indices for investors who take into consideration the corporate social responsibility (CSR) initiatives of each company. The DJSI Asia Pacific is specifically designed for companies in the developed Asia Pacific markets including Japan. This year, 145 companies were selected, including 62 Japanese companies, which are leading the way in terms of sustainability, among the 600 companies in the region.

For selection of the companies as the index components of DJSI Asia Pacific, RobecoSAM AG assesses companies based on questionnaire responses and information from public sources such as Annual Reports and websites. Leading sustainability-driven companies are selected as the index components every year based on the assessment in terms of long-term economic, environmental, and social criteria. Chugai participated in the assessment from last year, and won the inclusion in DJSI Asia Pacific for the second consecutive year as a result of its proactive activities based on the three criteria above.

Based on the business philosophy of "Innovation all for the patients," Chugai is committed to actively fulfill our social responsibilities as a healthcare company, by adding exceptional value through the creation of innovative medical products and services for the benefit of the medical community and human health around the world.

### **Contact:**

#### For Media

Chugai Pharmaceutical Co., Ltd

Media Relations Group, Corporate Communications Dept.,

Koki Harada

Tel: +81-3-3273-0881

E-mail: [pr@chugai-pharm.co.jp](mailto:pr@chugai-pharm.co.jp)

For Investors

Chugai Pharmaceutical Co., Ltd

Investor Relations Group, Corporate Communications Dept.,

Toshiya Sasai

Tel: +81-3-3273-0554

E-mail: [ir@chugai-pharm.co.jp](mailto:ir@chugai-pharm.co.jp)